

In the Claims

1. (Original) A contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15.
2. (Currently Amended) A The kit according to claim 1, wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
3. (Currently Amended) A The kit according to claim 1, ~~or~~ further comprising a contraceptively and/or therapeutically effective amount of an androgen ester.
4. (Currently Amended) A The kit according to claim 3, wherein the androgen ester is MENT undecanoate.
5. (Currently Amended) A The kit accordhig to claim 4, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-400 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 25-200 mg.

6. (Currently Amended) A The kit according to claim 5, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 50-200 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50-100 mg.

7. (Currently Amended) A The kit according to claim 6, wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.

8. (Currently Amended) A The kit according to claim 1, ~~or~~ further comprising a contraceptively and/or therapeutically effective amount of an estrogen.

9. (Canceled).

10. (Canceled).

11. (Canceled).

12. (Canceled).

13. (Canceled).

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Canceled).

18. (Currently Amended) A method of contraception and/or HRT, comprising:

administering to a subject a contraceptively and/or therapeutically effective amount of a long acting etonogestrel ester with a fatty-chain length of C7-C15.

19. (Currently Amended) A The method according to claim 18, wherein the ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.

20. (Currently Amended) A The method according to claim 18,
wherein a contraceptively and/or therapeutically effective amount
of a long-acting androgen ester is administered in conjunction
with the etonogestrel ester.

21. (Currently Amended) A The method according to claim 20,
wherein the etonogestrel ester is etonogestrel undecanoate and/or
etonogestrel decanoate and/or etonogestrel dodecanoate and the
androgen ester is MENT undecanoate.

22. (Currently Amended) A The method according to claim 21,
wherein the contraceptively and/or therapeutically effective
amount of MENT undecanoate is 50-400 mg and the contraceptively
and/or therapeutically effective amount of etonogestrel ester is
25-200 mg.

23. (Currently Amended) A The method according to claim 22,
wherein the contraceptively and/or therapeutically effective
amount of MENT undecanoate is 50-200 mg and the contraceptively
and/or therapeutically effective amount of etonogestrel ester is
50-100 mg.

24. (Currently Amended) A The method according to claim 23,

wherein the contraceptively and/or therapeutically effective amount of MENT undecanoate is 100 mg and the contraceptively and/or therapeutically effective amount of etonogestrel ester is 50 mg.

25. (Currently Amended) ~~A~~ The method according to claim 18, ~~or 19~~ wherein a contraceptively and/or therapeutically effective amount of an estrogen is administered in conjunction with the etonogestrel ester.

26. (Canceled).

27. (Canceled).

28. (Canceled).

29. (Currently Amended) A method of treating and/or preventing a female ~~gynaecological~~ gynecological disorder, comprising:

administering to a female subject a therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15 effective to treat and/or prevent the disorder.

30. (Currently Amended) A The method according to claim 29, wherein the etonogestrel ester is etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.

31. (Currently Amended) A The method according to claim 29, ~~or 30~~ wherein the female ~~gynaecological~~ gynecological disorder is selected from the group consisting of endometriosis, menorrhagia, meno-metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.